Developer docs
API playgroundTry for free, no card

Search company profiles

Orbits Oncology

Full company profile

uuid0003hht

Namestring
Orbits Oncology
Legal namestring
Orbits Oncology
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI image analysis software, organoid drug screening, live-cell imaging analysis, computational phenotyping platform, precision medicine analytics
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
AI Image Analysis Software for Organoid Drug Screening
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Software Platform Subscription
TypeSubscription Recurring
Description

Cloud-based AI image analysis platform accessible via app.orbits-oncology.com. Customers access the platform for analyzing imaging data from their in-vitro models. Pricing is quote-based, suggesting enterprise-level subscription contracts.

orbits-oncology.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise pricing for pharmaceutical and research institutions
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing; no public pricing tiers available. Platform access is provided through enterprise contracts tailored to customer requirements.

orbits-oncology.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Orbits Oncology develops and sells an AI-powered computational platform that converts live-cell imaging data from complex 3D in-vitro models (organoids, spheroids, co-cultures, microtissues) into quantitative, scalable phenotypic intelligence. The cloud-based platform delivers end-to-end workflows covering image upload, plate-layout management, segmentation, morphology classification, dynamic readouts, and export of analysis-ready results, and is sold via enterprise annual subscriptions to pharmaceutical companies and research institutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Automated detection of organoids and cell death areas without manual annotation
+2 more records
Product overview1 text field

Orbits Oncology offers a single unified AI-powered platform called the Orbits Platform. This platform provides a standardized workflow for analyzing complex in-vitro models through image capture, upload, segmentation, classification, and quantification of phenotypic responses. The platform supports applications in cancer/tumoroid drug screening (with metrics like NOGR, IC50, AUC), toxicology screening, cardiac contractility measurement, and neural model analysis. It integrates with major live-cell imaging systems (Tecan, Sartorius, Agilent, Molecular Devices, ZEISS, Revvity) and supports both brightfield and fluorescence modalities.

Product and service1 record
1Orbits Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-01-01
Description

Joint webinar partnership with Thermo Fisher Scientific on 'Advancing cancer organoid drug screening with novel media systems'. Colin Paul (Thermo Fisher) introduced OncoPro medium while Christophe Deben (Orbits) demonstrated imaging software capabilities for high-content analysis.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orbits Oncology

AI Image Analysis Software for Organoid Drug Screeningorbits-oncology.com

Orbits Oncology firmographics

Firmographics
Name
Orbits Oncology
Legal name
Orbits Oncology
Website
https://orbits-oncology.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Orbits Oncology industry classification

Industry
Product category
AI Image Analysis Software for Organoid Drug Screening
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI image analysis software
  • Organoid drug screening
  • Live-cell imaging analysis
  • Computational phenotyping platform
  • Precision medicine analytics

Where Orbits Oncology is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Orbits Oncology business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Software Platform Subscription: Cloud-based AI image analysis platform accessible via app.orbits-oncology.com. Customers access the platform for analyzing imaging data from their in-vitro models. Pricing is quote-based, suggesting enterprise-level subscription contracts.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise pricing for pharmaceutical and research institutions

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Orbits Oncology product offering

Product offering

Core offering

Orbits Oncology develops and sells an AI-powered computational platform that converts live-cell imaging data from complex 3D in-vitro models (organoids, spheroids, co-cultures, microtissues) into quantitative, scalable phenotypic intelligence. The cloud-based platform delivers end-to-end workflows covering image upload, plate-layout management, segmentation, morphology classification, dynamic readouts, and export of analysis-ready results, and is sold via enterprise annual subscriptions to pharmaceutical companies and research institutions.

Product overview

Orbits Oncology offers a single unified AI-powered platform called the Orbits Platform. This platform provides a standardized workflow for analyzing complex in-vitro models through image capture, upload, segmentation, classification, and quantification of phenotypic responses. The platform supports applications in cancer/tumoroid drug screening (with metrics like NOGR, IC50, AUC), toxicology screening, cardiac contractility measurement, and neural model analysis. It integrates with major live-cell imaging systems (Tecan, Sartorius, Agilent, Molecular Devices, ZEISS, Revvity) and supports both brightfield and fluorescence modalities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Orbits Platform

Quantifiable outcome

  • Automated detection of organoids and cell death areas without manual annotation
  • +2 more outcomes

Companies that use Orbits Oncology

Customer profile

Segments4 records

Ideal customer profiles2 records

Orbits Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability3 records

Feature6 records

Orbits Oncology partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Thermo Fisher ScientificcoreGTM or Marketing Partner · 1 January 2025Joint webinar partnership with Thermo Fisher Scientific on 'Advancing cancer organoid drug screening with novel media systems'. Colin Paul (Thermo Fisher) introduced OncoPro medium while Christophe Deben (Orbits) demonstrated imaging software capabilities for high-content analysis.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Orbits Oncology competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Orbits Oncology social profiles

Digital presence

Orbits Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orbits Oncology leadership team

Management profile

Number of profiles

Profiles6 records

Orbits Oncology funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orbits Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orbits Oncology

What does Orbits Oncology do?

Orbits Oncology develops and sells an AI-powered computational platform that converts live-cell imaging data from complex 3D in-vitro models (organoids, spheroids, co-cultures, microtissues) into quantitative, scalable phenotypic intelligence. The cloud-based platform delivers end-to-end workflows covering image upload, plate-layout management, segmentation, morphology classification, dynamic readouts, and export of analysis-ready results, and is sold via enterprise annual subscriptions to pharmaceutical companies and research institutions.

Is Orbits Oncology a public or private company?

Orbits Oncology is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Orbits Oncology founded?

Orbits Oncology was founded in 2019. It employs 1 to 10 people.

Where is Orbits Oncology based?

Orbits Oncology is headquartered in San Francisco, United States, in the North America region.

How does Orbits Oncology make money?

One revenue line is on record: software Platform Subscription.

Does Orbits Oncology have an API?

No public API is recorded for Orbits Oncology.

What industry is Orbits Oncology in?

Orbits Oncology's product category is AI Image Analysis Software for Organoid Drug Screening. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals